WAREHAM-Synomics Pharmaceutical Services, LLC, a leader in pre-clinical and clinical bioanalytical services, storage stability, and analytical testing services for the pharmaceutical industry, announced that the Generic Pharmaceutical Association (GPhA®) has named Synomics Pharma as a contract research organization member. GPhA represents the manufacturers and distributors of finished generic pharmaceuticals and bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry.
Synomics Pharma, a Smithers Group company, provides a broad portfolio of pre-clinical and clinical services in support of drug development through production. Michael Hochschwender, President and CEO of The Smithers Group, said, "Synomics Pharma's membership in the GPhA allows us to be at the forefront of issues facing the manufacturers and distributors of generic drugs. Our clients in the generics industry benefit as we actively develop our service offerings based on their needs and continually adapt our quality system to meet changing regulatory requirements. We are providing unique services which are specific to the needs of manufacturers and distributors in the generic industry."
"Synomics Pharma has a quality management system that is recognized as a benchmark throughout the generic and pharmaceutical industry," added John Pirro, Vice President and Chief Operating Officer of Synomics Pharma. "We see this membership as mutually beneficial for Synomics Pharma and for all GPhA members, as our mission is to provide quality service to the generics industry that exceeds expectations."
No comments:
Post a Comment